The protein-coding landscape of the human brain has long been considered largely mapped, yet a vast class of tiny molecules — microproteins encoded by short open reading frames once dismissed as genomic noise — may hold underappreciated influence over neurodegenerative disease. A comprehensive new atlas challenges that assumption by revealing over a thousand previously unannotated microproteins active in the very brain region most devastated by Alzheimer's disease.
Published in Nature Aging, the study catalogued 1,067 high-confidence microproteins in the human frontal cortex using rigorous spectral validation. Among these, a meaningful subset showed differential expression patterns in Alzheimer's disease brains that operated independently of changes in their parent canonical genes — suggesting microproteins can behave as autonomous functional actors rather than mere byproducts of larger transcripts. A particularly striking finding centered on a microprotein derived from the MKKS gene locus, which proved necessary for normal mitochondrial respiration in microglia, the brain's resident immune cells. Microglial metabolic dysfunction is increasingly recognized as a driver of neuroinflammation in Alzheimer's pathology, giving this mechanistic link immediate biological relevance.
This work lands at an important intersection in neuroscience: the growing recognition that the so-called "dark proteome" — molecules below conventional detection thresholds — may contain disease-relevant biology that has been systematically overlooked. Microprotein research remains young; most prior work has focused on cardiac and muscle tissue, making a frontal cortex atlas genuinely novel. Key limitations include the inherent cross-sectional nature of post-mortem brain tissue, which cannot establish causal disease timelines, and the challenge of distinguishing Alzheimer's-specific microprotein shifts from general aging effects. Nonetheless, the atlas itself represents durable infrastructure — a reference resource that could accelerate target discovery for years. The MKKS-derived microprotein finding, specifically linking microglial bioenergetics to a non-canonical molecular source, is potentially paradigm-shifting for how researchers model neuroinflammatory mechanisms.